01.11.1997 | ORIGINAL ARTICLE
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy
Erschienen in: Annals of Hematology | Ausgabe 4/1997
Einloggen, um Zugang zu erhalten